Clinical trials investigating the use of PARP inhibitors in patients with metastatic BC and somatic or germline BRCA2 or other DDR mutations are currently ongoing (NCT03397394, NCT03448718, and NCT03375307). This evidence concerns the gene BRCA2 and breast cancer.